Lixisenatide
China [CN] Lisilacil is a glucagon-like peptide-1 (GLP-1) receptor agonist, and GLP-1 is a hormone that helps normalize blood glucose levels. The safety and efficacy of this drug were evaluated in 10 clinical trials, which recruited a total of 5,400 patients with type 2 diabetes. In these trials, lixila was evaluated as a monotherapy and in combination with other FDA-approved diabetes drugs, including metformin, sulfonylureas, pioglitazone and basal insulin. In these trials, the use of licillacil improved the level of glycated hemoglobin (an indicator of blood sugar levels). In addition, in the cardiovascular outcome trial, more than 6,000 patients with type 2 diabetes at risk of atherosclerotic cardiovascular disease in ChemicalBook were treated with elicilala or placebo. The use of lisicera in these patients did not increase the risk of adverse cardiovascular events. Rissella should not be used to treat patients with type 1 diabetes or those with increased ketones in the blood or urine (diabetic ketoacidosis). The most common side effects associated with Lila are nausea, vomiting, headache, diarrhea and dizziness. Hypoglycemia is another common side effect in patients treated with elixylamine and other antidiabetic drugs such as sulfonylureas and/or basal drugs. In addition, severe hypersensitivity reactions (including allergies) have been reported in the clinical trials of Licilalai.
Click enlarge Image